Cloning in biology is the process of producing similar populations of genetically identical individuals that occurs in nature when organisms such as bacteria, insects or plants reproduce asexually. Cloning in biotechnology refers to processes used to create copies of DNA fragments (molecular cloning), cells (cell cloning), or organisms. The term also refers to the production of multiple copies of a product such as digital media or software.

The term ''clone'' is derived from ''κλῶνος'', the Greek word for "trunk, branch", referring to the process whereby a new plant can be created from a twig. In horticulture, the spelling ''clon'' was used until the twentieth century; the final ''e'' came into use to indicate the vowel is a "long o" instead of a "short o". Since the term entered the popular lexicon in a more general context, the spelling ''clone'' has been used exclusively.

In the United States, the human consumption of meat and other products from cloned animals was approved by the FDA on December 28, 2006, with no special labeling required. Cloned beef and other products have since been regularly consumed in the US without distinction. Such practice has met strong resistance in other regions, such as Europe, particularly over the labeling issue.

Molecular cloning

Molecular cloning refers to the process of making multiple molecules. Cloning is commonly used to amplify DNA fragments containing whole genes, but it can also be used to amplify any DNA sequence such as promoters, non-coding sequences and randomly fragmented DNA. It is used in a wide array of biological experiments and practical applications ranging from genetic fingerprinting to large scale protein production. Occasionally, the term cloning is misleadingly used to refer to the identification of the chromosomal location of a gene associated with a particular phenotype of interest, such as in positional cloning. In practice, localization of the gene to a chromosome or genomic region does not necessarily enable one to isolate or amplify the relevant genomic sequence. To amplify any DNA sequence in a living organism, that sequence must be linked to an origin of replication, which is a sequence of DNA capable of directing the propagation of itself and any linked sequence. However, a number of other features are needed and a variety of specialised cloning vectors (small piece of DNA into which a foreign DNA fragment can be inserted) exist that allow protein expression, tagging, single stranded RNA and DNA production and a host of other manipulations.

Cloning of any DNA fragment essentially involves four steps # fragmentation - breaking apart a strand of DNA # ligation - gluing together pieces of DNA in a desired sequence # transfection - inserting the newly formed pieces of DNA into cells # screening/selection - selecting out the cells that were successfully transfected with the new DNA Although these steps are invariable among cloning procedures a number of alternative routes can be selected, these are summarized as a 'cloning strategy'.

Initially, the DNA of interest needs to be isolated to provide a DNA segment of suitable size. Subsequently, a ligation procedure is used where the amplified fragment is inserted into a vector (piece of DNA). The vector (which is frequently circular) is linearised using restriction enzymes, and incubated with the fragment of interest under appropriate conditions with an enzyme called DNA ligase. Following ligation the vector with the insert of interest is transfected into cells. A number of alternative techniques are available, such as chemical sensitivation of cells, electroporation, optical injection and biolistics. Finally, the transfected cells are cultured. As the aforementioned procedures are of particularly low efficiency, there is a need to identify the cells that have been successfully transfected with the vector construct containing the desired insertion sequence in the required orientation. Modern cloning vectors include selectable antibiotic resistance markers, which allow only cells in which the vector has been transfected, to grow. Additionally, the cloning vectors may contain colour selection markers, which provide blue/white screening (alpha-factor complementation) on X-gal medium. Nevertheless, these selection steps do not absolutely guarantee that the DNA insert is present in the cells obtained. Further investigation of the resulting colonies must be required to confirm that cloning was successful. This may be accomplished by means of PCR, restriction fragment analysis and/or DNA sequencing.

Cellular cloning

Unicellular organisms

Cloning a cell means to derive a population of cells from a single cell. In the case of unicellular organisms such as bacteria and yeast, this process is remarkably simple and essentially only requires the inoculation of the appropriate medium. However, in the case of cell cultures from multi-cellular organisms, cell cloning is an arduous task as these cells will not readily grow in standard media.

A useful tissue culture technique used to clone distinct lineages of cell lines involves the use of cloning rings (cylinders). According to this technique, a single-cell suspension of cells that have been exposed to a mutagenic agent or drug used to drive selection is plated at high dilution to create isolated colonies; each arising from a single and potentially clonal distinct cell. At an early growth stage when colonies consist of only a few of cells, sterile polystyrene rings (cloning rings), which have been dipped in grease are placed over an individual colony and a small amount of trypsin is added. Cloned cells are collected from inside the ring and transferred to a new vessel for further growth.

Cloning in stem cell research

Somatic cell nuclear transfer, known as SCNT, can also be used to create embryos for research or therapeutic purposes. The most likely purpose for this is to produce embryos for use in stem cell research. This process is also called "research cloning" or "therapeutic cloning." The goal is not to create cloned human beings (called "reproductive cloning"), but rather to harvest stem cells that can be used to study human development and to potentially treat disease. While a clonal human blastocyst has been created, stem cell lines are yet to be isolated from a clonal source.

Organism cloning

Organism cloning (also called reproductive cloning) refers to the procedure of creating a new multicellular organism, genetically identical to another. In essence this form of cloning is an asexual method of reproduction, where fertilization or inter-gamete contact does not take place. Asexual reproduction is a naturally occurring phenomenon in many species, including most plants (see vegetative reproduction) and some insects. Scientists have made some major achievements with cloning, including the asexual reproduction of sheep and cows. There is a lot of ethical debate over whether or not cloning should be used. However, cloning, or asexual propagation, has been common practice in the horticultural world for hundreds of years.

Horticultural

The term ''clone'' is used in horticulture to refer to descendants of a single plant which were produced by vegetative reproduction or apomixis. Many horticultural plant cultivars are clones, having been derived from a single individual, multiplied by some process other than sexual reproduction. As an example, some European cultivars of grapes represent clones that have been propagated for over two millennia. Other examples are potato and banana. Grafting can be regarded as cloning, since all the shoots and branches coming from the graft are genetically a clone of a single individual, but this particular kind of cloning has not come under ethical scrutiny and is generally treated as an entirely different kind of operation.

Many trees, shrubs, vines, ferns and other herbaceous perennials form clonal colonies. Parts of a large clonal colony often become detached from the parent, termed fragmentation, to form separate individuals. Some plants also form seeds asexually, termed apomixis, e.g. dandelion.

Parthenogenesis

Clonal derivation exists in nature in some animal species and is referred to as parthenogenesis (reproduction of an organism by itself without a mate). This is an asexual form of reproduction that is only found in females of some insects, crustaceans and lizards. The growth and development occurs without fertilization by a male. In plants, parthenogenesis means the development of an embryo from an unfertilized egg cell, and is a component process of apomixis. In species that use the XY sex-determination system, the offspring will always be female. An example is the "Little Fire Ant" (''Wasmannia auropunctata''), which is native to Central and South America but has spread throughout many tropical environments.

Artificial cloning of organisms

Artificial cloning of organisms may also be called ''reproductive cloning''.

Methods

Reproductive cloning generally uses "somatic cell nuclear transfer" (SCNT) to create animals that are genetically identical. This process entails the transfer of a nucleus from a donor adult cell (somatic cell) to an egg that has no nucleus. If the egg begins to divide normally it is transferred into the uterus of the surrogate mother. Such clones are not strictly identical since the somatic cells may contain mutations in their nuclear DNA. Additionally, the mitochondria in the cytoplasm also contains DNA and during SCNT this DNA is wholly from the donor egg, thus the mitochondrial genome is not the same as that of the nucleus donor cell from which it was produced. This may have important implications for cross-species nuclear transfer in which nuclear-mitochondrial incompatibilities may lead to death.

Artificial ''embryo splitting'' or ''embryo twinning'' may also be used as a method of cloning, where an embryo is split in the maturation before embryo transfer. It is optimally performed at the 6- to 8-cell stage, where it can be used as an expansion of IVF to increase the number of available embryos. If both embryos are successful, it gives rise to monozygotic (identical) twins.

Dolly the Sheep

thumb|250px|Dolly, a Finn-Dorset ewe, was the first mammal to have been successfully cloned from an adult cell. She was cloned at the Roslin Institute in Scotland and lived there from her birth in 1996 until her death in 2003 when she was six. Her stuffed remains were placed at Edinburgh's Royal Museum, part of the National Museums of Scotland.

Dolly was publicly significant because the effort showed that the genetic material from a specific adult cell, programmed to express only a distinct subset of its genes, can be reprogrammed to grow an entirely new organism. Before this demonstration, it had been shown by John Gurdon that nuclei from differentiated cells could give rise to an entire organism after transplantation into an enucleated egg. However, this concept was not yet demonstrated in a mamallian system.

Cloning Dolly the sheep had a low success rate per fertilized egg; she was born after 237 eggs were used to create 29 embryos, which only produced three lambs at birth, only one of which lived. Seventy calves have been created and one third of them died young; Prometea took 277 attempts. Notably, although the first clones were frogs, no adult cloned frog has yet been produced from a somatic adult nucleus donor cell.

There were early claims that Dolly the Sheep had pathologies resembling accelerated aging. Scientists speculated that Dolly's death in 2003 was related to the shortening of telomeres, DNA-protein complexes that protect the end of linear chromosomes. However, other researchers, including Ian Wilmut who led the team that successfully cloned Dolly, argue that Dolly's early death due to respiratory infection was unrelated to deficiencies with the cloning process.

Water buffalo

On September 15, 2007, the Philippines announced its development of Southeast Asia’s first cloned water buffalo. The Philippine Council for Agriculture, Forestry and Natural Resources Research and Development (PCARRD), under the Department of Science and Technology in Los Baños, Laguna approved this project.

Species cloned

The modern cloning techniques involving nuclear transfer have been successfully performed on several species. Landmark experiments in chronological order: Tadpole: (1952) Many scientists questioned whether cloning had actually occurred and unpublished experiments by other labs were not able to reproduce the reported results. Carp: (1963) In China, embryologist Tong Dizhou produced the world's first cloned fish by inserting the DNA from a cell of a male carp into an egg from a female carp. He published the findings in a Chinese science journal. Mice: (1986) A mouse was the first mammal successfully cloned from an early embryonic cell. Soviet scientists Chaylakhyan, Veprencev, Sviridova, and Nikitin had the mouse "Masha" cloned. Research was published in the magazine "Biofizika" volume ХХХII, issue 5 of 1987. Sheep: (1996) From early embryonic cells by Steen Willadsen. Megan and Morag cloned from differentiated embryonic cells in June 1995 and Dolly the sheep from a somatic cell in 1997. Rhesus Monkey: Tetra (January 2000) from embryo splitting Gaur: (2001) was the first endangered species cloned. Cattle: Alpha and Beta (males, 2001) and (2005) Brazil Cat: CopyCat "CC" (female, late 2001), Little Nicky, 2004, was the first cat cloned for commercial reasons Dog: Snuppy, a male Afghan hound was the first cloned dog (2005). Rat: Ralph, the first cloned rat (2003) Mule: Idaho Gem, a john mule born 4 May 2003, was the first horse-family clone. Horse: Prometea, a Haflinger female born 28 May 2003, was the first horse clone. Water Buffalo: Samrupa was the first cloned water buffalo. It was born on February 6, 2009, at India's Karnal National Diary Research Institute but died five days later due to lung infection. Pyrenean Ibex (2009) was the first extinct animal (extinct 2000) to be cloned back to life; the clone lived for seven minutes before dying of lung defects. Camel: (2009) Injaz, is the first cloned camel.

Human cloning

Human cloning is the creation of a genetically identical copy of an existing or previously existing human. The term is generally used to refer to ''artificial'' human cloning; human clones in the form of identical twins are commonplace, with their cloning occurring during the natural process of reproduction. There are two commonly discussed types of human cloning: therapeutic cloning and reproductive cloning. Therapeutic cloning involves cloning adult cells for use in medicine and is an active area of research. Reproductive cloning would involve making cloned humans. A third type of cloning called replacement cloning is a theoretical possibility, and would be a combination of therapeutic and reproductive cloning. Replacement cloning would entail the replacement of an extensively damaged, failed, or failing body through cloning followed by whole or partial brain transplant.

The various forms of human cloning are controversial. There have been numerous demands for all progress in the human cloning field to be halted. Most scientific, governmental and religious organizations oppose reproductive cloning. The American Association for the Advancement of Science (AAAS) and other scientific organizations have made public statements suggesting that human reproductive cloning be banned until safety issues are resolved. Serious ethical concerns have been raised by the future possibility of harvesting organs from clones. Some people have considered the idea of growing organs separately from a human organism - in doing this, a new organ supply could be established without the moral implications of harvesting them from humans. Research is also being done on the idea of growing organs that are biologically acceptable to the human body inside of other organisms, such as pigs or cows, then transplanting them to humans, a form of xenotransplantation.

The first hybrid human clone was created in November 1998, by Advanced Cell Technologies. It was created from a man's leg cell, and a cow's egg whose DNA was removed. It was destroyed after 12 days. Since a normal embryo implants at 14 days, Dr Robert Lanza, ACT's director of tissue engineering, told the Daily Mail newspaper that the embryo could not be seen as a person before 14 days. While making an embryo, which may have resulted in a complete human had it been allowed to come to term, according to ACT: "[ACT's] aim was 'therapeutic cloning' not 'reproductive cloning'"

On January, 2008, Wood and Andrew French, Stemagen's chief scientific officer in California, announced that they successfully created the first 5 mature human embryos using DNA from adult skin cells, aiming to provide a source of viable embryonic stem cells. Dr. Samuel Wood and a colleague donated skin cells, and DNA from those cells was transferred to human eggs. It is not clear if the embryos produced would have been capable of further development, but Dr. Wood stated that if that were possible, using the technology for reproductive cloning would be both unethical and illegal. The 5 cloned embryos, created in Stemagen Corporation lab, in La Jolla, were destroyed.

Ethical issues of cloning

Because of recent technological advancements, the cloning of animals (and potentially humans) has been an issue. The Catholic Church and many religious organizations oppose all forms of cloning, on the grounds that life begins at conception. Judaism does not equate life with conception and, though some question the wisdom of cloning, Orthodox rabbis generally find no firm reason in Jewish law and ethics to object to cloning. From the standpoint of classical liberalism, concerns also exist regarding the protection of the identity of the individual and the right to protect one's genetic identity.

Gregory Stock is a scientist and outspoken critic against restrictions on cloning research. Bioethicist Gregory Pence also attacks the idea of criminalizing attempts to clone humans.

The social implications of an artificial human production scheme were famously explored in Aldous Huxley's novel ''Brave New World.''

On December 28, 2006, the U.S. Food and Drug Administration (FDA) approved the consumption of meat and other products from cloned animals. Cloned-animal products were said to be virtually indistinguishable from the non-cloned animals. Furthermore, companies would not be required to provide labels informing the consumer that the meat comes from a cloned animal.

Critics have raised objections to the FDA's approval of cloned-animal products for human consumption, arguing that the FDA's research was inadequate, inappropriately limited, and of questionable scientific validity. Several consumer-advocate groups are working to encourage a tracking program that would allow consumers to become more aware of cloned-animal products within their food.

Joseph Mendelson, legal director of the Center for Food Safety, said that cloned food still should be labeled since safety and ethical issues about it remain questionable.

Carol Tucker Foreman, director of food policy at the Consumer Federation of America, stated that FDA does not consider the fact that the results of some studies revealed that cloned animals have increased rates of mortality and deformity at birth.

Cloning extinct and endangered species

Cloning, or more precisely, the reconstruction of functional DNA from extinct species has, for decades, been a dream of some scientists. The possible implications of this were dramatized in the best-selling novel by Michael Crichton and high budget Hollywood thriller ''Jurassic Park''. In real life, one of the most anticipated targets for cloning was once the Woolly Mammoth, but attempts to extract DNA from frozen mammoths have been unsuccessful, though a joint Russo-Japanese team is currently working toward this goal. And in January 2011, it was reported by Yomiuri Shimbun that a team of scientists headed by Akira Iritani of Kyoto University had built upon research by Dr. Wakayama, saying that they will extract DNA from a mammoth carcass that had been preserved in a Russian laboratory and insert it into the egg cells of an African elephant in hopes of producing a mammoth embryo. The researchers said they hoped to produce a baby mammoth within six years.

In 2001, a cow named Bessie gave birth to a cloned Asian gaur, an endangered species, but the calf died after two days. In 2003, a banteng was successfully cloned, followed by three African wildcats from a thawed frozen embryo. These successes provided hope that similar techniques (using surrogate mothers of another species) might be used to clone extinct species. Anticipating this possibility, tissue samples from the last ''bucardo'' (Pyrenean Ibex) were frozen in liquid nitrogen immediately after it died in 2000. Researchers are also considering cloning endangered species such as the giant panda, ocelot, and cheetah. The "Frozen Zoo" at the San Diego Zoo now stores frozen tissue from the world's rarest and most endangered species.

In 2002, geneticists at the Australian Museum announced that they had replicated DNA of the Thylacine (Tasmanian Tiger), extinct about 65 years previous, using polymerase chain reaction. However, on February 15, 2005 the museum announced that it was stopping the project after tests showed the specimens' DNA had been too badly degraded by the (ethanol) preservative. On 15 May 2005 it was announced that the Thylacine project would be revived, with new participation from researchers in New South Wales and Victoria.

In January 2009, for the first time, an extinct animal, the Pyrenean ibex mentioned above was cloned, at the Centre of Food Technology and Research of Aragon, using the preserved DNA of the skin samples from 2001 and domestic goat egg-cells. (The ibex died shortly after birth due to physical defects in its lungs.) One of the continuing obstacles in the attempt to clone extinct species is the need for nearly perfect DNA. Cloning from a single specimen could not create a viable breeding population in sexually reproducing animals. Furthermore, even if males and females were to be cloned, the question would remain open whether they would be viable at all in the absence of parents that could teach or show them their natural behavior.

Cloning endangered species is a highly ideological issue. Many conservation biologists and environmentalists vehemently oppose cloning endangered species—mainly because they think it may deter donations to help preserve natural habitat and wild animal populations. The "rule-of-thumb" in animal conservation is that, if it is still feasible to conserve habitat and viable wild populations, breeding in captivity should not be undertaken in isolation.

In a 2006 review, David Ehrenfeld concluded that cloning in animal conservation is an experimental technology that, at its state in 2006, could not be expected to work except by pure chance and utterly failed a cost-benefit analysis. Furthermore, he said, it is likely to siphon funds from established and working projects and does not address any of the issues underlying animal extinction (such as habitat destruction, hunting or other overexploitation, and an impoverished gene pool). While cloning technologies are well-established and used on a regular basis in plant conservation, care must be taken to ensure genetic diversity. He concluded:

In science fiction

Cloning has been used in countless science fiction works throughout the years. Human cloning is usually the most popular kind that is used in these particular works, mainly due to fact that it brings up controversial questions of identity. For example, in C.J. Cherryh’s novel Cyteen, Aldous Huxley’s novel Brave New World, human cloning is a major plot device that not only drives the story along but also makes the reader think critically about what identity means.

Star Wars also portrays human cloning in ''Star Wars Episode II: Attack of the Clones'' and ''Star Wars Episode III: Revenge of the Sith'', in the form of the Grand Army of the Republic, an army of clone troopers. The Expanded Universe also has numerous examples of cloning, including the Thrawn trilogy, The Hand of Thrawn duology, and Clone Wars-era media.

See also

The President's Council on Bioethics

References

External links

Cloning Fact Sheet from Human Genome Project Information website.

'Cloning' Freeview video by the Vega Science Trust and the BBC/OU

The Reproductive Cloning Network. Cloning articles, resources and links

Cloning in Focus, an accessible and comprehensive look at cloning research from the University of Utah's Genetic Science Learning Center

Click and Clone. Try it yourself in the virtual mouse cloning laboratory, from the University of Utah's Genetic Science Learning Center

Cloning timeline: from CNN

"Cloning Addendum: A statement on the cloning report issues by the President's Council on Bioethics," The National Review, July 15, 2002 8:45am

Cloning educational resources and news from LiveScience.com

Ian Wilmut to quit cloning game

Category:Molecular biology Category:Cryobiology Category:Applied genetics

ar:استنساخ az:Klonlaşdırma bn:ক্লোনিং bs:Kloniranje bg:Клониране ca:Clonació cs:Klonování da:Kloning de:Klonen el:Κλωνοποίηση es:Clonación (biología) eo:Klonado eu:Klonazio fa:تاگ‌سازی fr:Clonage gl:Clonación ko:복제 (생물학) hi:प्रतिरूपण hr:Kloniranje id:Kloning ia:Clonage it:Clonazione he:שיבוט ka:კლონირება ht:Klòn lv:Klonēšana lt:Klonavimas jbo:mivyfu'i mk:Клонирање ml:ക്ലോണിംഗ് my:ပုံတူမျိုးပွားခြင်း nl:Klonen (biologie) ja:クローニング no:Kloning nn:Kloning pl:Klonowanie pt:Clonagem ru:Клонирование (биотехнология) sq:Klonimi sl:Kloniranje sr:Клонирање sh:Kloniranje su:Kloning fi:Kloonaus sv:Kloning ta:படியெடுப்பு tr:Klonlama uk:Клонування (біотехнологія) ur:تنسیل vi:Dòng hóa zh:克隆

Theodore Lockard Thomas (born 1920) is an American chemical engineer and attorney who, under the name Theodore L. Thomas, was the author of more than 50 science fiction short stories, published between the early 1950s to the late 1970s. He also collaborated on two novels with Kate Wilhelm, as well as producing stories under the pseudonyms of Leonard Lockard and Cogswell Thomas, and has been nominated for a Nebula award and a Hugo Award.

Bibliography

Collaborations with Kate Wilhelm

''The Clone'' (1965, expanded from his 1959 short story of the same name)

''The Year of the Cloud'' (1970)

Short stories

"The Far Look", in ''Astounding'', August 1956

"Ceramic Incident", in ''Astounding'', October 1956

"The Innocents’ Refuge", in ''Science Fiction Stories'', May 1957

"Satellite Passage", in ''If'', Dec 1958, and available in ''The Best of the Best Part One''

"Day of Succession", in ''Astounding'', August 1959

"The Clone", in ''Fantastic'', Dec 1959

"December 28th", in ''Playboy'', Dec 1959

"The Intruder", in ''Fantasy and Science Fiction'', Feb 1961

"Test", in ''Fantasy and Science Fiction'', April 1962

"The Lonely Man", in ''Galaxy'', April 1963

"The Ice Ages", in ''Fantasy and Science Fiction'', April 1965

"Science Springboard, The: Smog", article in ''Fantasy and Science Fiction'', Jan 1966

"The Doctor", in ''Orbit 2'', 1967

"The Weather on the Sun", in ''Orbit 8'', 1970 (Also available in ''The Science Fictional Solar System'')

"Early Bird (Cogswell)", in ''Astounding'', 1973 (Also available in ''The John W Campbell Memorial Anthology'')

Ker-Plop, in Asimov's Science Fiction, 1979

"The Splice", in ''Fantasy and Science Fiction'', March 1981

As Cogswell Thomas

"Paradise Regained", in ''Saving Worlds'', 1973

As Leonard Lockard

"The Lagging Profession" (1961)

"Improbable Profession" (1952), in ''Astounding'', September 1952 (co-written with Charles L. Harness)

External links

Theodore L. Thomas Short Story Guide

Discussion of Thomas and the accuracy of his predictions

Category:American science fiction writers Category:Living people Category:1920 births

it:Theodore Lockard Thomas

Coordinates	33°51′35.9″N151°12′40″N
Name	Robert Lanza
Birth place	Boston, Massachusetts, USA
Residence	Clinton, Massachusetts
Citizenship	United States
Workplaces	Advanced Cell Technology Wake Forest University School of Medicine
Alma mater	University of Pennsylvania
Known for	Stem cell biology, cloning, tissue engineering, biocentrism
Influences	Jonas Salk, Christiaan Barnard, and B.F. Skinner
Signature
Footnotes	}}

Robert Paul Lanza (born 11 February 1956) is an American Doctor of Medicine, scientist, Chief Scientific Officer of Advanced Cell Technology (ACT) and Adjunct Professor at the Institute for Regenerative Medicine, Wake Forest University School of Medicine.

Biography

Lanza was born in Boston, Massachusetts, and grew up south of there, in Stoughton, Massachusetts. Lanza "altered the genetics of chickens in his basement", and came to the attention of Harvard Medical School researchers when he appeared at the university with his results. Jonas Salk, B. F. Skinner, and Christiaan Barnard mentored Lanza over the next ten years. Lanza attended University of Pennsylvania, receiving BA and MD degrees. There, he was a Benjamin Franklin Scholar and a University Scholar. Lanza was a Fulbright Scholar. He currently resides in Clinton, Massachusetts.

Scientific work

Stem cell research

Lanza was part of the team that cloned the world's first early stage human embryos for the purpose of generating embryonic stem cells. Lanza demonstrated that techniques used in preimplantation genetic diagnosis could be used to generate embryonic stem cells without embryonic destruction.

In 2001 he was also the first to clone an endangered species (a Gaur), and in 2003, he cloned an endangered wild ox (a Banteng) from the frozen skin cells of an animal that had died at the San Diego Zoo nearly a quarter-of-a-century earlier.

Lanza and his colleagues were the first to demonstrate that nuclear transplantation could be used to reverse the aging process and to generate immune-compatible tissues, including the first organ grown in the laboratory from cloned cells.

Lanza showed that it is feasible to generate functional oxygen-carrying red blood cells from human embryonic stem cells under conditions suitable for clinical scale-up. The blood cells could potentially serve as a source of “universal” blood.

His team discovered how to generate functional hemangioblasts (a population of "ambulance" cells) from human embryonic stem cells. In animals, these cells quickly repaired vascular damage, cutting the death rate after a heart attack in half and restoring the blood flow to ischemic limbs that might otherwise have required amputatation.

Recently, Lanza and a team led by Kwang-Soo Kim at Harvard University reported a safe method for generating induced pluripotent stem (iPS) cells. Human iPS cells were created from skin cells by direct delivery of proteins, thus eliminating the harmful risks associated with genetic and chemical manipulation. This new method provides a potentially safe source of patient-specific stem cells for translation into the clinic.

Clinical trials for blindness

Lanza’s team at Advanced Cell Technology has succeeded in getting stem cells to grow into retinal cells. Using this technology some forms of blindness may be curable, including macular degeneration and Stargardt disease, a currently untreatable form eye disease that causes blindness in teenagers and young adults.

Advanced Cell Technology has received approval from the Food and Drug Administration for human trials using human embryonic stem cells to treat degenerative eye diseases. This treatment for eye disease uses stem cells to re-create a type of cell in the retina that supports the photoreceptor cells needed for vision. These cells, called retinal pigment epithelium (RPE), are often the first to die off in age-related macular degeneration and other eye diseases, which in turn leads to loss of vision. Several years ago, Lanza’s team found that human embryonic stem cells could be a source of RPE cells, and subsequent studies found that these cells could restore vision in animal models of macular degeneration.

In recent studies, the same team of researchers showed that their stem-cell therapy provides a long-term benefit in animal models of vision loss. The retinal cells achieved near normal function in animals that otherwise would have gone blind.

Biocentrism

In 2007, Lanza's article titled "A New Theory of the Universe" appeared in ''The American Scholar''. The essay addressed Lanza's theory, biocentrism, which places biology above the other sciences. Lanza's book "How Life and Consciousness are the Keys to Understanding the Universe" followed in 2009. Reception to Lanza's theory has been mixed.

Awards and public commentary

Lanza received a 2005 Wired magazine "Rave Award" for medicine, and a 2006 Mass High Tech journal “All Star” award for biotechnology.

Publications

Lanza has authored and co-edited books on topics involving tissue engineering, cloning, stem cells, and world health.

Books

1984 ''Heart Transplantation: The Present Status of Orthotopic and Heterotopic Heart Transplantation'' ISBN 0-85200-862-7

1985 ''Medical Science and the Advancement of World Health'' ISBN 0-03-071734-5

1994 ''Pancreatic Islet Transplantation: Volume I Procurement of Pancreatic Islets'' ISBN 1-57059-133-4

1994 ''Pancreatic Islet Transplantation: Volume II Immunomodulation of Pancreatic Islets'' ISBN 1-57059-134-2

1994 ''Pancreatic Islet Transplantation: Volume III Immunoisolation of Pancreatic Islets'' ISBN 1-57059-135-0

1996 ''One World: The Health and Survival of the Human Species in the 21st Century'' ISBN 0-929173-33-3

1996 ''Yearbook of Cell and Tissue Transplantation'' ISBN 0-7923-3844-8

1997 ''Principles of Tissue Engineering'' ISBN 1-57059-342-6

1999 ''Cell Encapsulation Technology and Therapeutics'' ISBN 0-8176-4010

2000 ''Xeno: The Promise of Transplanting Animal Organs into Humans'' ISBN 0-19-512833-8

2000 ''Principles of Tissue Engineering, Second Edition'' ISBN 0-12-436630-9

2002 ''Methods of Tissue Engineering'' ISBN 0-12-436636-8

2002 ''Principles of Cloning'' ISBN 0-12-174597-X

2004 ''Handbook of Stem Cells: Volume 1 Embryonic Stem Cells'' ISBN 0-12-436642-2

2004 ''Handbook of Stem Cells: Volume 2 Adult and Fetal Stem Cells'' ISBN 0-12-436644-9

2006 ''Essentials of Stem Cell Biology'' ISBN 0-12-088442-9

2006 ''Methods in Enzymology: Volume 418 Embryonic Stem Cells'' ISBN 0-12-373648-X

2006 ''Methods in Enzymology: Volume 419 Adult Stem Cells'' ISBN 0-12-373650-1

2006 ''Methods in Enzymology: Volume 420 Stem Cell Tools and Other Experimental Protocols'' ISBN 0-12-373651-X

2007 ''Principles of Tissue Engineering, Third Edition'' ISBN 0-12-370615-7

2008 ''Principles of Regenerative Medicine'' ISBN 978-0-12-369410-2

2009 ''Biocentrism: How Life and Consciousness are the Keys to Understanding the Universe'' ISBN 978-1933771-69-4

2009 ''Essential Stem Cell Methods'' ISBN 978-0-12-374741-9

2009 ''Essentials of Stem Cell Biology, Second Edition'' ISBN 978-0-12-374729-7

2009 ''Foundations of Regenerative Medicine'' ISBN 978-0123750853

2010 ''Principles of Regenerative Medicine, Second Edition'' ISBN 978-0123814227

References

External links

Personal website: blog, and archive of books, articles and news.

Advanced Cell Technology website

Lanza's essays on ''The Huffington Post''

Category:1956 births Category:Wake Forest University faculty Category:University of Pennsylvania alumni Category:Living people

fa:رابرت لنزا